Robert K Gieseler
Overview
Explore the profile of Robert K Gieseler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
601
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marwitz F, Hadrich G, Redinger N, Besecke K, Li F, Aboutara N, et al.
ACS Infect Dis
. 2024 Aug;
10(9):3222-3232.
PMID: 39136125
Liposomal formulations of antibiotics for inhalation offer the potential for the delivery of high drug doses, controlled drug release kinetics in the lung, and an excellent safety profile. In this...
2.
Akkiz H, Gieseler R, Canbay A
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063116
The burden of chronic liver disease is globally increasing at an alarming rate. Chronic liver injury leads to liver inflammation and fibrosis (LF) as critical determinants of long-term outcomes such...
3.
Gieseler R, Baars T, Ozcurumez M, Canbay A
J Pers Med
. 2024 May;
14(5).
PMID: 38793074
This Editorial precedes the Special Issue entitled "Novel Challenges and Therapeutic Options for Liver Diseases". Following a historical outline of the roots of hepatology, we provide a brief insight into...
4.
Canbay A, Gotze O, Kucukoglu O, Weinert S, Croner R, Baars T, et al.
Pharmaceutics
. 2024 Apr;
16(4).
PMID: 38675168
l-Ornithine- l-aspartate (LOLA) reduces toxic ammonium (NH) plasma levels in hepatic encephalopathy. NH detoxification/excretion is achieved by its incorporation into urea and glutamine via activation of carbamoyl phosphate synthetase 1...
5.
Gieseler R, Schreiter T, Canbay A
Z Gastroenterol
. 2023 Jan;
61(1):83-94.
PMID: 36623546
Aging is characterized by the progressive decline of biological integrity and its compensatory mechanisms as well as immunological dysregulation. This goes along with an increasing risk of frailty and disease....
6.
Baars T, Gieseler R, Patsalis P, Canbay A
Metabolism
. 2022 Mar;
130:155179.
PMID: 35283187
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Importantly, NAFLD increases the risk for cardiovascular disease (CVD). A causal relationship has been substantiated. Given the pandemic...
7.
Kreimeyer H, Buechter M, Best J, Gieseler R, Katsounas A, Sowa J, et al.
Dig Dis
. 2022 Feb;
41(2):259-267.
PMID: 35193135
Background: Acute liver failure (ALF) occurs as a rare, sudden, extensive loss of liver function in a previously healthy liver. In advanced cases, ALF may require liver transplantation (LT). Available...
8.
Huck B, Thiyagarajan D, Bali A, Boese A, Besecke K, Hozsa C, et al.
Adv Healthc Mater
. 2022 Feb;
11(11):e2102117.
PMID: 35112802
Nontuberculous mycobacterial infections rapidly emerge and demand potent medications to cope with resistance. In this context, targeted loco-regional delivery of aerosol medicines to the lungs is an advantage. However, sufficient...
9.
Schreiter T, Gieseler R, Vilchez-Vargas R, Jauregui R, Sowa J, Klein-Scory S, et al.
Pharmaceutics
. 2021 Dec;
13(12).
PMID: 34959291
A transcriptome-wide analysis of human liver for demonstrating differences between young and old humans has not yet been performed. However, identifying major age-related alterations in hepatic gene expression may pinpoint...
10.
Leven A, Gieseler R, Schlattjan M, Schreiter T, Niedergethmann M, Baars T, et al.
Adipocyte
. 2021 Nov;
10(1):558-573.
PMID: 34743657
The role of visceral white adipose tissue (vWAT) in the progression of non-alcoholic liver disease (NAFLD) with its sub entities non-alcoholic fatty liver and steatohepatitis (NAFL; NASH) is underinvestigated. We...